Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in relapsed/refractory AL amyloidosis
NCT03499808Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2018
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in systemic light chain amyloidosis, sponsored by SWOG Cancer Research Network. Started Jun 2018; status: completed.
02
Drugs
isatuximab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT03499808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499808.